medigraphic.com

2019, Number 2

Next >>

Vet Mex 2019; 6 (2)

Canine lymphoma: Pathological and clinical characteristics of patients treated at a referral hospital

Sánchez D, Sánchez-Verin R, Corona H, Gutiérrez A, Núñez-Ochoa L, Paredes J, Cesarman-Maus G

Language: English/Spanish
References: 43
Page: 1-11
PDF size: 357.34 Kb.


ABSTRACT

Non-Hodgkin’s lymphomas are common canine cancers with variable demographic and clinical presentations. Their pathological characterization and treatment lag far behind those of humans. We describe consecutive lymphoma patients detected over a one-year period at the National Autonomous University of Mexico (UNAM). Of 4,512 dogs: 220 (4.9%) had a cancer diagnosis, of which 27 (0.6%) had lymphoma (12% of cancer patients). We found an association with Miniature Schnauzers, which represented 18.5% (5/27) of lymphoma patients, but it was only 6.4% (288/4,512) of the dogs studied in this time period (p ‹ 0.011). Miniature Schnauzers and mongrels together constituted nearly half of lymphoma cases. Mean age at diagnosis was 7.5 years (3-14), with a female to male ratio of 1.7:1. We found no correlation between lymphoma and castration status. Most patients presented nodal involvement (80%), were in advanced stages III/IV (90%) and had B-cell versus T-cell tumors (64%/36%). Only two histopathological patterns were seen, both with diffuse nodal-replacement by large immunoblast and/ or centroblast-like cells; one having numerous tingible-body macrophages which are suggestive of a high proliferative rate. Chemotherapy was given to 15 patients (65%) with an overall response of 73% (3 complete responses/ 8 partial responses) and a mean overall survival of 219 days (4-586; SD±185). One cutaneous lymphoma-patient achieved partial response (PR) with lomustine/prednisone, and treatment was still ongoing at 548 days. Earlier diagnosis, better lymphoma subtype distinction, and specific curative treatments are needed.


REFERENCES

  1. Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol. 2014;159(3-4):192-201.

  2. Vail D. Canine lymphoma and lymphoid leukemias. Feline lymphoma and leukemia. In: Withrow SJ, Vail DM, Page RL, editors. Withrow & MacEwen’s small animal clinical oncology. Saint Louis, Mo: Saunders; 2013. p. 608-50.

  3. Boerkamp KM, Teske E, Boon LR, Grinwis GC, van den Bossche L, Rutteman GR. Estimated incidence rate and distribution of tumours in 4,653 cases of archival submissions derived from the Dutch golden retriever population. BMC Vet Res. 2014;10:34.

  4. Zwingenberger AL, Kent MS, Shi C, Taylor SL, Chen X, Lam KS. Affinity of the alpha4- beta1 integrin-targeting peptide LLP2A to canine lymphoma. Vet Immunol Immunopathol. 2012;145(1-2):298-304.

  5. Dobson JM. Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci. 2013;2013:941275.

  6. Theilen GH, Madewell BR, Gardner M B. Hematopoietic neoplasms, sarcomas and related conditions. Vet Cancer Med. 1987;2:392-407.

  7. Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C, et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol. 2010;47(3):414-33.

  8. Teske E. Canine malignant lymphoma: a review and comparison with human non-Hodgkin’s lymphoma. Vet Q. 1994;16(4):209-19.

  9. Vail DM, Kisseberth WC, Obradovich JE, Moore FM, London CA, MacEwen EG, et al. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin’s lymphoma. Exp Hematol. 1996;24(7):807-15.

  10. Marconato L. The staging and treatment of multicentric high-grade lymphoma in dogs: a review of recent developments and future prospects. Vet J. 2011;188(1):34-8.

  11. Vail DM, Michels GM, Khanna C, Selting KA, London CA, Veterinary Cooperative Oncology G. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)—A Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28-37.

  12. MacDonald VS, Thamm DH, Kurzman ID, Turek MM, Vail DM. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma? J Vet Intern Med. 2005;19(5):732-6.

  13. Devitt JJ, Maranon DG, Ehrhart EJ, Bachand AM, Lana SE, LaRue SM. Correlations between numerical chromosomal aberrations in the tumor and peripheral blood in canine lymphoma. Cytogenet Genome Res. 2009;124(1):12-8.

  14. Dorn CR, Taylor DO, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am J Vet Res. 1967;28(125):993-1001.

  15. Edwards DS, Henley WE, Harding EF, Dobson JM, Wood JL. Breed incidence of lymphoma in a UK population of insured dogs. Vet Comp Oncol. 2003;1(4):200-6.

  16. Álvarez F. J. AG, Chávez G. Histological and immunophenotypic study of canine lymphoma in the center of Mexico. Vet Mexico. 2009;40:141-55.

  17. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, et al. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer. 1990;66(3):480-90.

  18. Priester WA. Canine lymphoma: relative risk in the boxer breed. J Natl Cancer Inst. 1967;39(5):833-45.

  19. Villamil JA, Henry CJ, Hahn AW, Bryan JN, Tyler JW, Caldwell CW. Hormonal and sex impact on the epidemiology of canine lymphoma. J Cancer Epidemiol. 2009;2009:591753.

  20. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005;65(13):5654-61.

  21. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr. 1980(54):1-210.

  22. Núñez L. Linfosarcoma en perros. In: Muncha C. J. SCE, Pellegrino, editor. Consulta rápida en la clínica diaria. Buenos Aires: Intermédica; 2005. p. 649-52.

  23. Howell DA, Warburton F, Ramirez AJ, Roman E, Smith AG, Forbes LJ. Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma. Br J Cancer. 2015;113(7):1114-20.

  24. Owen LN, World Health Organization. TNM Classification of Tumours in Domestic Animal. Geneva: World Health Organization; 1980.

  25. Schmidt JM, North SM, Freeman KP, Ramiro-Ibanez F. Canine paediatric oncology: retrospective assessment of 9522 tumours in dogs up to 12 months (1993-2008). Vet Comp Oncol. 2010;8(4):283-92.

  26. Regan RC, Kaplan MS, Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. Vet Comp Oncol. 2013;11(4):287-95.

  27. Aniołek O, Gajewski Z, Gizi􀆙ski S. Application of flow cytometry in diagnosing lymphomas in dogs and cats. Central-European journal of immunology. 2014;39(3):327-30.

  28. Willmann M, Mullauer L, Guija de Arespacochaga A, Reifinger M, Mosberger I, Thalhammer JG. Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. Veterinary immunology and immunopathology. 2009;128(4):359-65.

  29. Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, Coffey D, et al. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol. 2005;42(4):468-76.

  30. Guija de Arespacochaga A, Schwendenwein I, Weissenbock H. Retrospective study of 82 cases of canine lymphoma in Austria based on the working formulation and immunophenotyping. J Comp Pathol. 2007;136(2-3):186-92.

  31. Sueiro FA, Alessi AC, Vassallo J. Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. J Comp Pathol. 2004;131(2-3):207-13.

  32. Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol. 2011;48(1):198-211.

  33. Vezzali E, Parodi AL, Marcato PS, Bettini G. Histopathologic classification of 171 cases of canine and feline non-Hodgkin lymphoma according to the WHO. Vet Comp Oncol. 2010;8(1):38-49.

  34. Flood-Knapik KE, Durham AC, Gregor TP, Sanchez MD, Durney ME, Sorenmo KU. Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol. 2013;11(4):272-86.

  35. Lurie DM, Lucroy MD, Griffey SM, Simonson E, Madewell BR. T-cell-derived malignant lymphoma in the boxer breed. Vet Comp Oncol. 2004;2(3):171-5.

  36. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discovery. 2013;3(7):770-81.

  37. Nelson RW, Couto CG. Small animal internal medicine. St. Louis, Mo: Mosby; 1998.

  38. Squire RA, Bush M, Melby EC, Neeley LM, Yarbrough B. Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy. J Natl Cancer Inst. 1973;51(2):565-74.

  39. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med. 1993;7(5):289-95.

  40. Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol. 2013;11(4):306-15.

  41. Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2000;14(2):120-4.

  42. Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med. 2002;16(6):704-9.

  43. MacEwen EG, Patnaik AK, Wilkins RJ. Diagnosis and treatment of canine hematopoietic neoplasms. Vet Clin North Am. 1977;7(1):105-18.




2020     |     www.medigraphic.com